anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present study will be included pregnant women who are in the third trimester of pregnancy (from the 27th gestational week), aged 18-40 years, with regular follow-up with the obstetrician and who present adequate systemic health during pregnancy, without the need for absolute rest. In subprojects 1 and 2, pregnant women who tested positive for IgM and IgG serology will be evaluated. Pregnant women who test positive (n = 60) and pregnant women who test negative (n = 60) for coronavirus sars-cov-2 will be selected, making a total of 120 pregnant women. In project 1 the sample will be divided into 4 groups of pregnant women: GOC- with excessive weight gain and with COVID19 (n = 30), GOSC- without excessive weight gain and COVID19, GNC- without excessive weight gain and with COVID19 (n = 30) and GNSC- without excessive weight gain and without COVID19 (n = 30). For subproject 2 that will have proteomic analysis, the number of 10 patients for each group (GOC, GOSC, GNC and GNSC) will be adopted according to previous protocols for saliva proteomic analysis. Subprojects 3 and 4 will consist of babies, to identify possible congenital changes during the fetal period. In subproject 3, the 120 babies of the pregnant women participating in the study will be divided into BC (n = 60) and BSC (n = 60), which will be evaluated for the occurrence of the congenital syndrome associated with the presumed maternal infection by coronavirus sars- cov-2. In project 4, the sample will consist of 20 babies with congenital malformations for the case group (BM) and 20 control babies without congenital malformations (BSM), exposed to COVID19.
NEW MATERIAL:A compound shown by the formula I (R1 is group shown by the formula II or III; R2 is H or group shown by the formula IV or V). USE:A bisdesmoside in a compound shown by the formula I is a dissolution auxiliary for a useful substance such as steroid, etc., having small water solubility in a compound shown by the formula I. A monodesmonoside is an auxiliary for drug absorption. PREPARATION:Firstly, cyclic bisdesmoside shown by the formula VI is extracted from tu-bei-mu of Bolbo stema pani (Maxim.) Franquest, a perennial herb belonging to the family Cucurbitaceae. Then, the compound, for example, is heated in an aqueous solution of a strong acid such as sulfuric acid, etc., hydrolyzed, the reaction solution is treated with water saturated butanol, further the butanol layer is concentrated under reduced pressure and purified silica gel chromatography, etc., to give a compound shown by the formula I wherein R1 is group shown by the formula II and R2 is H.
The invention discloses a medicament for treating rhinitis and a preparation method of the medicament. The medicament comprises the following Chinese medicinal herbs in parts by weight: 15 parts of honeysuckle, 11 parts of baical skullcap root, 6 parts of dandelion, 10 parts of dittany bark, 10 parts of divaricate saposhnikovia root, 5 parts of periostracum cicada, 5 parts of tripterygium wilfordii, 8 parts of moutan bark, 8 parts of retinervus luffae fructus and 8 parts of rhizoma typhonii. The preparation method comprises the steps of: preparing the Chinese medicinal herbs in parts, adding water of which the addition amount is 6 times that of the Chinese medicinal herbs, boiling, decocting for 30-40min by using slow fire, and filtering decoction dregs to obtain decoction. The Chinese medicinal herbs in the medicament are common medicinal herbs, and are easily available. The preparation method is simple. Through properly proportioning all Chinese medicinal herbs, the nasal cavity stimulation of a patient can be reduced during application, a patient has a comfortable treatment experience, and the treatment effect is good.
Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
The pharmacokinetics and tolerability of tramadol hydrochloride and acetaminophen in patients with renal impairment has not been studied. Based on studies using tramadol extended-release tablets, the excretion of tramadol and metabolite M1 is reduced in patients with creatinine clearance of less than 30 mL/min. In patients with creatinine clearances of less than 30 mL/min, it is recommended that the dosage of tramadol hydrochloride and acetaminophen not exceed 2 tablets every 12 hours. [see Dosage and Administration ( 2.2)] . The total amount of tramadol and M1 removed during a 4 hour dialysis period is less than 7% of the administered dose based on studies using tramadol alone. Monitor closely for signs of respiratory depression, sedation, and hypotension.
Cases are to be enrolled at five to ten centers. The same center may be included in both arms. Conversely, a center may choose to participate in only a single arm. The enrollment goal is approximately 36 - 72 cases per center for Cohort 1 (cementless) and 15 - 30 cases per center for Cohort 2 (cemented) , and will vary dependent upon the number of participating centers. Although a goal is presented, there is no maximum limit to the number of cases that a center may enroll. In the event that a center far exceeds the enrollment goal, Stryker may ask the center to cease enrollment so as not to skew the data. All participating centers will comply with the federal regulations regarding patient informed consent and Institutional Review Board (IRB) or Ethics Committee (EC) approval. Non-compliance of a study center may result in termination of the center's participation in the study.
The application provides a traditional Chinese medicine compound for treating lumbar disc herniation and a preparation method thereof, wherein the traditional Chinese medicine compound comprises the following raw materials: semen Ziziphi Spinosae preparata, radix Angelicae sinensis, rhizoma Ligustici Chuanxiong, rhizoma corydalis, radix Paeoniae alba, radix rehmanniae Preparata, fructus Chaenomelis, Eucommiae cortex, Bombyx Batryticatus, radix Cynanchi Paniculati, parched Atractylodis rhizoma and Glycyrrhrizae radix. The spina date seed is a monarch drug with the effects of nourishing the liver, calming the heart and soothing the nerves. Prepared rehmannia root is good at nourishing yin and blood, Chinese angelica is good at replenishing blood and nourishing liver, harmonizing blood and regulating menstruation, white paeony root is good at nourishing blood, nourishing liver and harmonizing ying, szechuan lovage rhizome is good at activating blood and promoting qi circulation, and regulating qi and blood, eucommia bark is sweet in taste and warm in nature and tonifying, is an essential medicine for tonifying liver and kidney, and is a ministerial medicine together. Bombyx Batryticatus enters liver, lung and stomach meridians, has effects of calming endogenous wind and relieving spasm, dispelling pathogenic wind and relieving pain, radix Cynanchi Paniculati enters liver and stomach meridians, dispelling pathogenic wind and eliminating dampness, activating qi-flowing and dredging collaterals, parched Atractylodis rhizoma has effects of invigorating spleen and qi, eliminating dampness and promoting diuresis, and rhizoma corydalis has effects of promoting blood circulation, regulating qi-flowing and relieving pain, and is used as adjuvant drugs together. Licorice root, radix Glycyrrhizae coordinates the effects of the other drugs in the recipe. The whole formula has the effects of strengthening the liver, nourishing the blood, dredging collaterals and relieving pain. The traditional Chinese medicine composition is clinically applicable to the lumbar intervertebral disc protrusion diagnosed by western medicine, and the lumbocrural pain, the limb numbness and other diseases differentiated by the traditional Chinese medicine are liver and kidney deficiency.
Breast cancer is a major health concern for women everywhere and a major killer of women. Malignant tumors may be distinguished from benign ones, allowing for early diagnosis of this disease. Therefore, doctors need an accurate method of diagnosing tumors as either malignant or benign. Even if therapy begins immediately after diagnosis, some cancer cells may persist in the body, increasing the risk of a recurrence. Metastasis and recurrence are the leading causes of death from breast cancer. Therefore, detecting a return of breast cancer early has become a pressing medical issue. Evaluating and contrasting various Machine Learning (ML) techniques for breast cancer and recurrence prediction is crucial to choosing the best successful method. Inaccurate forecasts are common when using datasets with a large number of attributes. This study addresses the need for effective feature selection and optimization methods by introducing Recursive Feature Elimination (RFE) and Grey Wolf Optimizer (GWO), in response to the limitations observed in existing approaches. In this research, the performance evaluation of methods is enhanced by employing the RFE and GWO, considering the Wisconsin Diagnostic Breast Cancer (WDBC) and Wisconsin Prognostic Breast Cancer (WPBC) datasets taken from the UCI-ML repository. Various preprocessing techniques are applied to raw data, including imputation, scaling, and others. In the second step, relevant feature correlations are used with RFE to narrow down candidate discriminative features. The GWO chooses the best possible combination of attributes for the most accurate result in the next step. We use seven ML classifiers in both datasets to make a binary decision. On the WDBC and WPBC datasets, several experiments have shown accuracies of 98.25% and 93.27%, precisions of 98.13% and 95.56%, sensitivities of 99.06% and 96.63%, specificities of 96.92% and 73.33%, F1-scores of 98.59% and 96.09% and AUCs of 0.982 and 0.936, respectively. The hybrid approach's superior feature selection improved the accuracy of breast cancer performance indicators and recurrence classification.
The EMD-U treatment lasts eight weeks, in which two EMD-U sessions of 60 minutes and two phone calls take place in the first three weeks. In the five following weeks, patients are phoned twice to ask for their experiences with the practicing at home. An important part of EMD-U consists of homework exercises. These homework exercises comprise to practice/apply the intervention as learned during the sessions with the therapist, in those situations wherein the urge to scratch their skin is present. In the text below, we will explain in more detail what the treatment protocol entails. Patients in this condition receive the EMD-U treatment in addition to the care as usual.
Participants will initially complete a baseline assessment assessing study eligibility. The intervention includes 8 core in-person group sessions and 8 optional in-person group sessions (1.5 hours each) targeting standard weight loss and pain treatment content and eight individual phone calls (30 minutes each) focusing primarily on increasing environmental reward and positive affect. Intervention sessions may be delivered online through protected health information (PHI) Zoom. Group sessions will be delivered every-other week and phone calls will occur every-other week (during weeks with no group). Sessions will be administered by a study interventionist with bachelors- or masters-level training and certification in health education or a related field (e.g., Certified Health Education Specialist), and materials will be developed to be appropriate for delivery by this level of training, given the potential for greater availability of these types of health professionals.
Participants will receive Elafibranor 80 mg in Fasting State on Day 1 of Period 1 followed by a washout period of a maximum of 28 days. Participants will then receive Elafibranor 80 mg in Fed State on Day 1 of Period 2.
BACKGROUND: Perioperative myocardial injury/infarction (PMI) following noncardiac surgery is a frequent cardiac complication. This study aims to evaluate PMI risk and explore preoperative assessment tools of PMI in patients at increased cardiovascular (CV) risk who underwent noncardiac surgery under the surgical and medical co-management (SMC) model.
METHODS: A prospective cohort study that included consecutive patients at increased CV risk who underwent intermediate- or high-risk noncardiac surgery at the Second Medical Center, Chinese PLA General Hospital, between January 2017 and December 2022. All patients were treated with perioperative management by the SMC team. The SMC model was initiated when surgical intervention was indicated and throughout the entire perioperative period. The incidence, risk factors, and impact of PMI on 30-day mortality were analyzed. The ability of the Revised Cardiac Risk Index (RCRI), frailty, and their combination to predict PMI was evaluated.
RESULTS: 613 eligible patients (mean [standard deviation, SD] age 73.3[10.9] years, 94.6% male) were recruited consecutively. Under SMC, PMI occurred in 24/613 patients (3.9%). Patients with PMI had a higher rate of 30-day mortality than patients without PMI (29.2% vs. 0.7%, p = 0.00). The FRAIL Scale for frailty was independently associated with an increased risk for PMI (odds ratio = 5.91; 95% confidence interval [CI], 2.34-14.93; p = 0.00). The RCRI demonstrated adequate discriminatory capacity for predicting PMI (area under the curve [AUC], 0.78; 95% CI, 0.67-0.88). Combining frailty with the RCRI further increased the accuracy of predicting PMI (AUC, 0.87; 95% CI, 0.81-0.93).
CONCLUSIONS: The incidence of PMI was relatively low in high CV risk patients undergoing intermediate- or high-risk noncardiac surgery under SMC. The RCRI adequately predicted PMI. Combining frailty with the RCRI further increased the accuracy of PMI predictions, achieving excellent discriminatory capacity. These findings may aid personalized evaluation and management of high-risk patients who undergo intermediate- or high-risk noncardiac surgery.
Cell cycle checkpoints, oncogene-induced senescence and programmed cell death represent intrinsic barriers to tumorigenesis. Protein phosphatase magnesium-dependent 1 (PPM1D) is a negative regulator of the tumour suppressor p53 and has been implicated in termination of the DNA damage response. Here, we addressed the consequences of increased PPM1D activity resulting from the gain-of-function truncating mutations in exon 6 of the PPM1D. We show that while control cells permanently exit the cell cycle and reside in senescence in the presence of DNA damage caused by ionising radiation or replication stress induced by the active RAS oncogene, RPE1-hTERT and BJ-hTERT cells carrying the truncated PPM1D continue proliferation in the presence of DNA damage, form micronuclei and accumulate genomic rearrangements revealed by karyotyping. Further, we show that increased PPM1D activity promotes cell growth in the soft agar and formation of tumours in xenograft models. Finally, expression profiling of the transformed clones revealed dysregulation of several oncogenic and tumour suppressor pathways. Our data support the oncogenic potential of PPM1D in the context of exposure to ionising radiation and oncogene-induced replication stress.
Disclosed is a composition of denatured plasma protein; at least one metal, metal ion or metal salt; and a pharmaceutically-acceptable carrier. The denatured plasma protein is produced by heating the plasma to about 80 degrees Celsius with sodium bicarbonate and then separating the denatured plasma protein from non-denatured plasma. The denatured plasma protein is then mixed with at least one metal, metal ion or metal salt; and heated to at least 50 degrees Celsius to produce a mixture to which a pharmaceutically-acceptable carrier is then added. The composition is capable of: a) healing tissue disruptions; and/or b) modulating apoptosis; and/or c) modulating the activity of TNF-alpha; and/or d) modulating the activity of TNF-alpha receptor; and/or e) modulating the activity of TACE; and/or f) modulating the activity of a caspase, especially caspase-1, caspase-3 and/or caspase-9 The method for preparing the composition is also disclosed. The metals in particular are selected from nickel, sodium, copper, zinc, cobalt, iron, magnesium, manganese, potassium, silver and mercury. The use of the composition in a medicament to treat lesions, wounds, microbial infections, burns, ulcers, soft tissue injuries, connective tissue injuries, inflammation and dermal conditions, especially sunburn, is also disclosed.
WebMD, a smartphone-based tool for learning about blood pressure and other health conditions. Enhanced usual care participants receive a wireless blood pressure cuff for accurate blood pressure measurement and automated storage on a digital platform. All participants in the experimental arm receive a smartphone for the 6-month intervention duration and the home-based blood pressure cuff.
Patients will be included after signing informed consent. After inclusion, patients will continue on standard dosing schedule of secukinumab (i.e. subcutaneous injections once a week for 5 weeks (300 mg) followed by subcutaneous injections every 4 weeks). During each study visit blood will be taken in order to quantify Ctroughs and/or anti-drug antibodies towards secukinumab. In addition, Psoriasis Area and Severity Index (PASI) and Investigator's Global Assessment (IGA) score will be evaluated by a physician. Patients complete the Dermatology Life Quality Index (DLQI) and European quality of life EQ-5D instrument at each visit.
A process for the conversion of glycoside substituted taxanes to taxol and related compounds that can serve as precursors to taxol. The process includes the oxidation of glycoside substituted taxanes to convert the glycoside to the hydroxyl group. The oxidation can occur in the presence of an acid or followed by treatment with acid. Application of the process to 7-xylosyl taxol ("XT") yields taxol; application to other glycoside substituted taxanes forms compounds that can serve as precursors for taxol. The process includes the formation of certain new taxol related intermediate compounds having a hemialdal at the C-7 site on the taxane ring, which hemialdal can then be converted to taxol or taxol precursors. Since glycoside substituted taxanes are isolated with taxol from naturally occurring biomass, their conversion to taxol using the process of the present invention significantly improves the total yield of taxol from natural sources.
FIELD: medicine, surgery, urology. SUBSTANCE: invention proposes the use of furacillin ozonized solution 1:5000 at ozone concentration 500 mcg/l for bladder washing out once per a day up to appearance of clear washing out water followed by filling bladder cavity with indicated solution for 10-15 min and its removal from bladder after the final sanitation using finely dispersed flow of the above indicated solution. The latter is formed under pressure 80 atm, diameter of particles in outlet nozzle is 0.7 mm obtained in apparatus UGO-1. Treatment course is 7-10 days. Method can be used for prophylaxis of suppurative-septic complications in urological operations accompanying with epicystotomy applying. EFFECT: improved quality of bladder sanitation and results of treatment of patients with pathology of urinary system. 1 ex
Retrospective observational single centre study: Soft tissue and bone diameters are assessed in MRI and CT scans of patients. Data is compared with recommendations of intraosseus needle producers to assess whether the information provided by the producers can be optimised. Study sites are head of humerus bone, distal femur, proximal and distal tibia in accordance with recommended intraosseus access sites. Data is gathered from patients who undergo either MRI or CT scanning for any disease and where bone at the IO puncture site is accessible for measurements required for this study.

Primary and secondary outcome parameters will be assessed at one time only, i.e. when the patient has received MRI or CT scan for the diagnostic work up of their primary disease. Data collection for a given patient in this study can be completed within one session, e.g. 5-10 minutes. No additional investigation is required for this
Table 4 lists the drugs that have been tested in in vitro binding or in vivo drug interaction studies with colesevelam and/or drugs with postmarketing reports consistent with potential drug-drug interactions. Orally administered drugs that have not been tested for interaction with colesevelam, especially those with a narrow therapeutic index, should also be administered at least 4 hours prior to WELCHOL. Alternatively, the physician should monitor drug levels of the co-administered drug.

In an in vivo drug interaction study, WELCHOL and warfarin coadministration had no effect on warfarin drug levels. This study did not assess the effect of WELCHOL and warfarin coadministration on INR. In postmarketing reports, concomitant use of WELCHOL and warfarin has been associated with reduced INR. Therefore, in patients on warfarin therapy, the INR should be monitored before initiating WELCHOL and frequently enough during early WELCHOL therapy to ensure that no significant alteration in INR occurs. Once the INR is stable, continue to monitor the INR at intervals usually recommended for patients on warfarin. [See Post-marketing Experience (6.2)]
A pilot study first tested the feasibility of the approach and the sensitivity of existing outcome measures to changes in group social interaction. Following amendments to the pilot protocol, twelve new participants with severe ABI were recruited from a residential post-acute rehabilitation centre in April 2015. An experimental parallel group design was used to compare a peer-led group intervention to a staff-led social activity group. Participants were randomised to a peer-led intervention (n=6) or a staff-led social activity group (usual care) (n=6). The groups met twice a week for 8 weeks. A peer with severe ABI was trained separately to facilitate interaction in the peer-led group. The training took place in 16 individual sessions over 4 weeks. Group behaviour was measured twice at baseline, after intervention and at maintenance (4 weeks) using measures meeting reliability, validity and responsiveness criteria tested in the pilot study.
BACKGROUND: Higher neighborhood deprivation is associated with hypertension diagnosis in youth. In this study, we assess if there is an association between neighborhood deprivation and antihypertensive therapy prescription among insured youth with a primary hypertension diagnosis.
METHODS: Using a retrospective cross-sectional design, we assessed the proportion of youth with a diagnosis of primary hypertension prescribed antihypertensive therapy. We evaluated the proportion of youth prescribed antihypertensive therapy and compared prescribing patterns by area deprivation index (ADI), age, sex, obesity diagnosis, race, ethnicity, and duration of Medicaid coverage.
RESULTS: Of the 65,452 non-pregnant Delaware Medicaid recipients, 8-18 years of age, 1,145 (1.7%) had an International classification of diseases (ICD)-9/ICD-10 diagnosis of primary hypertension; 165 of the 1,145 (14%) were prescribed antihypertensive therapy. Factors associated with a greater odds of prescription by multivariable logistic regression were age, obesity diagnosis, and duration of Medicaid full benefit coverage. Odds of antihypertensive therapy prescription did not vary by race, ethnicity, or ADI.
CONCLUSIONS: Antihypertensive therapy prescription rates are poor despite national guideline recommendations. Among youth receiving Delaware Medicaid between 2014 and 2019, prescription proportions were highest among youth of older age, with an obesity diagnosis, and among youth with longer duration of Medicaid benefit coverage. Although high area deprivation has been shown to be associated with the diagnosis of hypertension, high vs. low area deprivation was not associated with greater antihypertensive therapy prescription among youth with primary hypertension. Our finding of a mismatch between hypertension diagnosis and antihypertensive therapy prescription highlights a potential disparity in antihypertensive therapy prescription in youth.